Syntax Research’s CRISPR Therapeutics CRSP Stock Holding History

Syntax Research’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-250	Closed	-$12.2K	–	176
2025 Q2	$12.2K	Hold	250	–	–	0.01%	131
2025 Q1	$8.51K	Hold	250	–	–	0.01%	143
2024 Q4	$9.84K	Hold	250	–	–	0.01%	147
2024 Q3	$11.7K	Hold	250	–	–	0.01%	144
2024 Q2	$13.5K	Hold	250	–	–	0.01%	123
2024 Q1	$17K	Hold	250	–	–	0.01%	123
2023 Q4	$15.7K	Hold	250	–	–	0.01%	123
2023 Q3	$11.3K	Buy	+250	New	+$12.9K	0.01%	134

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Syntax Research's CRSP Position: Q3 2025 in Review

Syntax Research sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 250 shares — an estimated $12.2K sold.

Syntax Research first reported a position in CRSP in Q3 2023 and held it in 8 quarters. The position peaked at $17K in Q1 2024. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Syntax Research reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Syntax Research sold 250 CRISPR Therapeutics shares in Q3 2025, an estimated $12.2K.
Syntax Research first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 8 quarters.
Syntax Research's CRISPR Therapeutics position peaked at $17K in Q1 2024.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Syntax Research's 13F filing for Q3 2025, filed 4 Nov 2025.